EyePoint (EYPT) Pharmaceuticals announced positive interim 16-week data for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E, for patients with diabetic macular edema, DME. DURAVYU 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity, BCVA, and anatomical control versus the aflibercept control arm. A favorable safety and tolerability profile continued for both DURAVYU arms. The 2.7mg dose is also being evaluated in the Phase 3 pivotal trials for wet AMD. The Company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint announces first patient dosed in global Phase 3 LUGANO trial
- ANI Pharmaceuticals price target raised to $62 from $60 at Truist
- Biotech Alert: Searches spiking for these stocks today
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls